> But I don't think I've found anyone who is a domain expert who thinks granting everyone access to raw modes wouldn't meaningfully increase risk.

It depends how capable these raw models are. Biology as a field depends most on real-world knowledge, which is an expensive capability for open models targeting widespread deployment. It's quite plausible that even Opus 4 would be a lot more capable in these domains than the best universally accessible "raw models" today, quite unlike other domains such as coding or pure math. The securebio.org benchmark has spotty representation of openly available models, but it does show Kimi 2.5 being no more capable than GPT 5 mini, and clearly below o4-mini and Opus 4.0; which may be a plausible summary of where things stand today.